Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002233 · ClinicalTrials.gov registry record · Phase 2
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
A Phase 2 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002233: Completed Phase 2 study, sponsored by Glaxo Wellcome.
NCT00002233 is a Phase 2 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002233, a Phase 2 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment. The effects of this combination of drugs on the immune system and the level of HIV in the body are studied also. The four-drug combination includes lamivudine, abacavir, amprenavir, and indinavir.
Interventions
- DRUG Lamivudine
- DRUG Indinavir sulfate
- DRUG Abacavir sulfate
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 2 |
What the finished NCT00002233 record still lists
NCT00002233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 4 interventions - of which Lamivudine is the first listed.
NCT00002233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002233 about?
NCT00002233 is a clinical study titled "A Study of a Combination of Four Drugs in Patients With Recent HIV Infection". The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment. The effects of this combination of drugs on the immune system and the level of HIV in the body are studied also. The four-...
What is the current status of trial NCT00002233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00002233?
The interventions under investigation include: Lamivudine (DRUG), Indinavir sulfate (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002233?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002233's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer